

A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. diagnosis of adenocarcinoma of the prostate 2. spread (metastatic) to other organs or bone 3. one chemotherapy treatment for hormone sensitive prostate cancer is allowed 4. previous treatment required, study staff will review 5. able to care for self with little help

Exclusion Criteria:

1. prior chemotherapy with docetaxel or cabazitaxel for CRPC 2. other severe medical conditions, study staff will review

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Castration Resistant Metastatic Prostate Cancer (CRPC), Prostate cancer

More Information

Description: The goal of this current study is to test whether men with prostate cancer that is getting worse after treatment with hormone therapy and abiraterone respond better to alternating treatment with testosterone and enzalutamide vs. enzalutamide alone. We are testing to see which is better at stopping tumor growth that can be seen on a bone scan or CT scan and the effect of each regimen on lowering Prostate Specific Antigen (PSA values). Participants will be in the study for 6 to 24 months.

Study Contact: Emmanuel Antonarakis - anton401@umn.edu

Principal Investigator: Emmanuel Antonarakis

IRB

Number: SITE00001730

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.